PHILADELPHIA, PA and KFAR SABA, ISRAEL, August 10, 2015—ControlRad Systems Inc., a medical device company developing innovative products that dramatically reduce damaging radiation exposure to patients and physicians during fluoroscopic procedures, announced today that a fourth patent (U.S. Patent Number 9,095,283) was granted from the U.S. Patent and Trademark Office. The company continues to build its extensive portfolio and has an additional nine patents filed.
“We are thrilled at yet another issued patent further demonstrating our innovative approach,” said Guillaume Bailliard, Chief Executive Officer. “Long‐term ionizing radiation exposure is increasingly being recognized as a threat to physicians performing fluoroscopy procedures and ControlRad Systems patented products can play a critical role in mitigating the threat.”
ControlRad is a privately-held medical technology company developing innovative products that dramatically reduce the lifetime risk of radiation exposure from fluoroscopically guided interventional procedures (FGIP) for patients and healthcare professionals. These products are designed to improve safety without compromising image quality or workflow. This is accomplished with an integrated set of proprietary components which optimize the X-ray beam to deliver optimal image quality in the clinically-relevant region of focus of the physician while maintaining appropriate resolution in the periphery. ControlRad is headquartered in Philadelphia and has engineering development facilities in Kfar Saba, Israel. For more information, visit www.controlrad.com.